of the top 10 commercial plans cover Ozempicof the top 10 commercial health plans cover Ozempic
100%
of plans require PAof plans require prior authorization
$25/mo
with Ozempic Savings Card
2
savings & assistance programs
Copay
Check your patient's planFind savings for your patient
Compare GLP-1 Alternatives
See how Ozempic stacks up on access, cost, and PA burden — the factors that affect whether your patient can actually get on therapy.
Access Metric
OzempicSemaglutide
zepbound
mounjaro
wegovy
rybelsus
Plan Coverage% of commercial plans
>80%Best
PA Required% of plans requiring PA
100%
Copay w/ SavingsWith manufacturer card
$25
Savings ProgramsTotal available
2Most
Copay
Approved IndicationsFDA-approved uses
Type 2 DiabetesCardiovascular RiskChronic Kidney Disease
Get better comparisons with Prescriber.AI
See which alternative has the best coverage, lowest PA burden, and best savings for your patient's specific insurance.
Get better comparisons with Prescriber.AISee which alternative has the best coverage, lowest PA burden, and best savings for your patient's specific insurance.
Formulary InformationFormulary Information resource
Get form
Let us handle your prior authsJust enter your patient's info and we'll:
Verify eligibility with the payer.
Pull the right PA forms directly from the payer.
Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Get StartedFree to start · HIPAA compliant
Prescribing Information
Indications
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
To reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Dosing Titration
0.25
0.25 mgFirst 4 weeksTitration
0.5
0.5 mgAfter 4 weeksMaintenance
1
1 mg≥4 weeks laterEscalation
2
2 mg≥4 weeks laterMax dose
0.25
0.25 mgFirst 4 weeksTitration
0.5
0.5 mgAfter 4 weeksMaintenance
1
1 mg≥4 weeks laterEscalation
2
2 mg≥4 weeks laterMax dose
Subcutaneous injection · once weekly · any time of day · with or without meals. 0.25 mg is for initiation only and not effective for glycemic control. Maximum: 2 mg once weekly.
Common Side Effects
Nausea
20%
Vomiting
9%
Diarrhea
9%
Abdominal pain
6%
Constipation
3%
Contraindications
A personal or family history of MTC or in patients with MEN 2.
A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC.
Full FDA Prescribing Information
Access the complete FDA-approved prescribing label for Ozempic, including approved indications, recommended dosage & administration schedules, contraindications, warnings & precautions, adverse reactions, drug interactions, and use in specific populations.View full prescribing information
Check medication interactionsMay interact with insulin and sulfonylureas (increased hypoglycemia risk). May affect absorption of oral medications due to delayed gastric emptying. Monitor patients closely when initiating or adjusting concomitant oral medications.
Check full interactions →
Resources
Patient Education Materials8
Clinical Information10
Insurance Resources1
Dosage & administration
DOSAGE AND ADMINISTRATION
Administer once weekly at any time of day, with or without meals. (2.1 )
Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly. (2.2 )
If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. (2.2 )
If additional glycemic control is needed, increase the dosage to 2 mg once weekly after at least 4 weeks on the 1 mg dosage. (2.2 )
To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage. (1 , 2.2 )
If a dose is missed, administer within 5 days of missed dose. (2.1 )
Inject subcutaneously in the abdomen, thigh, or upper arm. (2.1 )
Important Administration Instructions
Inspect OZEMPIC visually before use. It should appear clear and colorless. Do not use OZEMPIC if particulate matter and coloration is seen.
Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.
Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm. Instruct patients to use a different injection site each week when injecting in the same body region.
When using OZEMPIC with insulin, instruct patients to administer as separate injections and to never mix the products. It is acceptable to inject OZEMPIC and insulin in the same body region, but the injections should not be adjacent to each other.
The day of weekly administration can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours).
If a dose is missed, administer OZEMPIC as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once-weekly dosing schedule.
Recommended Dosage
Recommended Initiation Dosage
Initiate OZEMPIC with a dosage of 0.25 mg injected subcutaneously once weekly for 4 weeks. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.7 ), Adverse Reactions (6.1 )].
After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg once weekly.
Recommended Maintenance and Maximum Dosages for Glycemic Control
The recommended maintenance dosage is 0.5 mg, 1 mg, or 2 mg, injected subcutaneously once weekly, based on glycemic control.
If additional glycemic control is needed after at least 4 weeks on the:
0.5 mg dosage, the dosage may be increased to 1 mg once weekly.
1 mg dosage, the dosage may be increased to 2 mg once weekly.
The maximum recommended dosage is 2 mg once weekly.
Recommended Maintenance Dosage in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Increase the dosage to the maintenance dosage, 1 mg once weekly, after at least 4 weeks on the 0.5 mg dosage.
PubMed™ news
Last year
Publication date
Article Type
Format
5 articles
Reset Filters
5 most recent articles for Ozempic, view all articles on PubMed™
Journal Article • 2026 May
Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes.
Journal Article • 2026 May
Beyond GLP-1 Monotherapy: Novel Multi-Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes.
Journal Article • 2026 May
Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts.
Journal Article • 2026 May
Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).
Journal Article • 2026 May
Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?
Show the latest PubMed™ articles for OzempicI certify that I'm a U.S. healthcare provider
Frequently Asked Questions
What does the FDA boxed warning for Ozempic state?
What is Ozempic FDA-approved to treat?
What is the recommended dosage and administration for Ozempic?
What dosage forms and strengths are available for Ozempic?
Who should not receive Ozempic?
What warnings and precautions apply to Ozempic?
What are the most common adverse reactions with Ozempic?
What drug interactions should I consider with Ozempic?